MARKET

LUNG

LUNG

Pulmonx Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

41.70
-0.95
-2.23%
Opening 10:52 10/27 EDT
OPEN
43.00
PREV CLOSE
42.65
HIGH
43.37
LOW
41.50
VOLUME
25.87K
TURNOVER
--
52 WEEK HIGH
52.00
52 WEEK LOW
37.64
MARKET CAP
1.41B
P/E (TTM)
-400.5764
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Pulmonx to Report Third Quarter 2020 Financial Results on November 10, 2020
GlobeNewswire · 4d ago
Pulmonx Announces Closing of Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares
REDWOOD CITY, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, today announced the closing of its initial public offering of 11,500,000
GlobeNewswire · 10/05 21:01
3 Biotech Companies Are Making Their Market Debuts
C4 Therapeutics, Immunome, and Oncorus are the latest to go public.
Barrons.com · 10/02 15:23
Biotech Pulmonx Set to Start Trading
The company raised $190 million after pricing its deal above its expected range.
Barrons.com · 10/01 15:57
Pulmonx shares soar 118% in trading debut
Shares of Pulmonx, a maker of treatments for lung diseases including emphysema, rose 118% in their trading debut Thursday, after the company's initial public...
MarketWatch · 10/01 15:36
Pulmonx Corporation Announces Pricing of its Upsized Initial Public Offering
Pulmonx Corporation (“Pulmonx”) today announced the pricing of its upsized initial public offering of 10,000,000 shares of its common stock at a price of $19.00 per share, for gross proceeds of $190,000,000 million, before underwriting discounts and commissions and offering expenses payable by Pulmonx
GlobeNewswire · 10/01 02:36
Forecast
EPSBVPSCFPS
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LUNG. Analyze the recent business situations of Pulmonx Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About LUNG
Pulmonx Corporation is a commercial-stage medical technology company. The Company is focused on providing planning tools and treatments for obstructive lung disease. Its solutions include Zephyr Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform. The Company's solutions offer minimally invasive treatment option for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its solution provides bronchoscopic lung volume reduction without surgery. The Zephyr Valves are indicated for bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valves are placed in the airways to occlude the diseased parts of the lung, allowing trapped air to escape.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Pulmonx Corp stock information, including NASDAQ:LUNG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LUNG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LUNG stock methods without spending real money on the virtual paper trading platform.